GLB1 and GM1 gangliosidosis: Our results suggest that whereas ganglioside and oligosaccharide substrates that accumulate in the absence of β-gal contribute to fatal and devastating neurological disease progression in GM1 gangliosidosis, gene therapy approaches to add back the missing GLB1 gene product also have the potential to promote toxicity.